Company intelligence / Profile preview

coeruleus

Rosh Pinna, Israelpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~5
Development stage: Other

Overview

coeruleus is developing a high-concentration sublingual spray formulation of flumazenil ("flumup") for rapid reversal of lingering sedative effects after use of hypnotic-sedative sleep medications. The company targets the large market for sleep disorder treatments and aims to address unmet needs related to next-day impairment from common prescription sleeping pills. No published clinical results are available as yet.

Therapeutic areas: Neurology
Modalities: Small moleculeSublingual spray formulation
Industry: Biotech

Partnerships

COS Israel

Beyond the preview

Go deeper on coeruleus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coeruleus.

Explore the full profile